SecBot SecBot
SECBOTREPLAY Home › Report › LGVN

LGVN · Longeveron disclosed that the FDA rejected the primary endpoint (RVEF)…

Longeveron Inc. · 8-K filed May 8, 2026 at 16:20 ET

At the news

BEARISHIMPACT 7/10

8-K filed May 8, 2026 at 16:20 ET

Longeveron disclosed that the FDA rejected the primary endpoint (RVEF) of its Phase 2b ELPIS II trial for HLHS, and the FDA no longer considers the trial 'pivotal.' Top-line results are still expected in August 2026. This is a material regulatory setback for a micro-cap biotech with no approved products.

  • FDA stated primary endpoint (RVEF) is not appropriate to demonstrate efficacy
  • FDA no longer refers to ELPIS II as a pivotal trial
  • FDA willing to discuss results after trial completion
  • Top-line results expected August 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access